Richard Busby Joins OncoBay leading Business Development

OncoBay Clinical - Richard Busby - LeadershipTAMPA, Fla. (July 07, 2020) — OncoBay Clinical, Inc., a full-service boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, is pleased to announce the expansion of their leadership team. OncoBay welcomes Richard Busby as Vice President of Marketing and Business Development.

“It’s exciting to join a team of clinical research professionals with such a great track record of success in the Oncology space with the support of the scientific leadership of Moffitt Cancer Center,” said Busby.

Busby brings over 25 years of experience in clinical research from both a clinical operations and business development background. He has a proven track record of success in companies such as PPD and Pharmalink FHI, which later became Novella Clinical. Busby began his career as a clinical research associate and project manager for a variety of phase I to IV clinical trials. He joined Novella Clinical in 2006, leading the functional outsourcing team before moving to a focus on oncology programs, supporting Novella’s Biotech and Pharma sponsors.

As a business development professional, Busby draws from his operational foundation, bringing practical experience and perspective to discussions with prospective clients. He has worked to assemble and offer a variety of creative models to meet his client’s needs – from functional service models to customized preferred providers of targeted services to full turn-key CRO solutions. Busby has experience in forging strategic relationships with emerging biotech customers, as well as assembling and serving on governance committees focused on key customer metrics and delivery of customized, proactive development solutions.

“The more time we spend upfront truly learning about a prospective sponsor’s clinical programs, understanding their operational challenges and learning their overall clinical and commercial goals, the better performance we can provide from day one. Given Richard’s strong background in both operations and business development, I have no doubt that he will lay the foundation in our client relationships to accomplish this.” said Krystyna Kowalczyk, president and CEO of OncoBay Clinical.

To learn more about OncoBay Clinical, please visit

About OncoBay Clinical

OncoBay Clinical is a boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full- service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As a wholly owned, for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit and follow us on Facebook, Twitter and LinkedIn.  


Deborah Turunjian

OncoBay Clinical, Vice-President Business Operations


dturunjian@oncobay.comOncoBay Clinical - Richard Busby - Leadership

The Latest News & Events


Take Advantage of OncoBay’s Innovative Approach


Submit a Request for Proposal

Submit Proposal

OncoBay is now Kapadi


Once three entities – OncoBay Clinical, Clinscience, and Exom Group s.r.l – now we stand as one, bringing forth a symphony of expertise and seamless operations. To celebrate our unity, we re-brand under the banner of Kapadi, and embark on a new chapter of exceptional service in oncology clinical research.

Kapadi is not just a name; it's a testament to our fusion. It signifies the our standing as a global CRO powerhouse committed to accelerating groundbreaking cancer therapies that uplift patients worldwide. From conceptualizing studies, navigating regulations, and analyzing data, we provide a comprehensive array of services designed to empower your oncology clinical trials.




This pop-up will auto-close in 10 seconds.

This will close in 5 seconds